v3.25.2
Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Research and development expenses        
Expenses incurred $ 91 $ 249 $ 155 $ 624
Less- government grants (155) (41) (335)
Research and development expenses, net 91 94 114 289
Marketing expenses 1 28 3 196
General and administrative expenses 194 236 422 531
Total operating loss 286 358 539 1,016
Financial expenses, net 415 8 935 7
Loss for the period $ 701 $ 366 $ 1,474 $ 1,023
Basic loss per common stock $ (0.01) $ (0.01) $ (0.02) $ (0.015)
Dilutive loss per common stock $ (0.01) $ (0.01) $ (0.02) $ (0.015)
Weighted average number of common stock, basic 73,755,083 70,281,511 72,423,280 70,106,284
Weighted average number of common stock, diluted 73,755,083 70,281,511 72,423,280 70,106,284

Source